Participants List
(Academia) |
Ain-Shams University, Egypt |
Akershus University Hospital, Norway |
Albany Medical College, USA |
Albert Eintein College of Medicine, Beth Israel Medicine, USA |
Altai State Technical University, Russia |
American Heart Association, USA |
Antwerp University Hospital, Antwerp, Belgium |
Ariel University Center In Samaria, Israel |
Ariel University Center of Samaria, Israel |
Aristotle University of Thessaloniki, Greece |
Athens Medical School, Greece |
Baylor College of Medicine, USA |
Biological Sciences Federal UniversityBrazil. |
Bournemouth Diabetes and Endocrine Centre, UK |
Buck Institute for Age Research, USA |
Cardiff School of Biosciences, UK |
Carleton University, Canada |
Center for Advancement of Drug Research and Evaluation (CADRE), USA |
Centre Cardiologique du Nord, France |
Centre de Recherche des Cordeliers France |
Chang-Gung Memorial Hospital, Taiwan |
Charles University, Czech Republic |
Chiba University Graduate School of Medicine, Japan |
China Medical University, Taiwan |
Chinese Academy of Sciences, China |
Christian Medical College, India |
Chubu University, Japan |
Chung-Ang University, Korea |
D. Cotugno Hospital, Italy |
David Geffen School of Medicine at UCLA, USA |
Deakin University, Australia |
Deakin University, Australia |
Docenti Unina University, Italy |
East Carolina University, USA |
Ege University, Turkey |
Emory University School of Medicine, USA |
ERS, ATS, Geneva, Switzerland |
European Medicines Agency (EMEA), UK |
Fernando Pessoa University, Portugal |
German Research School for Simulation Sciences GmbH, Germany |
Goethe University Frankfurt, Germany |
Government Of India, India |
Graduate School of Medical Sciences Cornell University, USA |
Harvard Medical School, USA |
Helsinki University Central Hospital, Finland |
Hong Kong University, China |
Hungarian Academy of Sciences, Hungary |
Ibaraki. University, Japan |
IIT Madras, India |
Illinois College of Medicine, USA |
Imperial College Kidney and Transplant Institute, UK |
Imperial College London, UK |
Indiana University Melvin and Bren Simon Cancer Center, USA |
Institut Charles Gerhardt UMR 5253, MACS Team, France |
Institute for Biological Sciences, National Research Council of Canada, Canada |
Institute for Molecular Science, Japan |
Institute of Biomedical Chemistry (IBMC RAMS), Russia |
Institute of Physiologically Active Compounds, Russia |
Institute of PLA of Chinese Medicine, China |
International University of Health and Welfare Graduate School, Japan |
IRCCS Neuromed, Italy |
IRCM. Inserm U896, CRLC Val d'Aurelle-Parc Euromdecine, France |
Jackson State University, USA |
Jackson State University, USA |
Janssen Pharmaceutica N.V., Belgium |
Janssen Pharmaceutica N.V., Belgium |
Johns Hopkins University School of Medicine, USA |
Juntendo University Urayasu Hospital, Japan |
| King Abdulaziz University, Kingdom of Saudi Arabia |
King's College London, UK |
Korea University, Korea |
Kursk State Technical University, Russian |
Lake Erie College of Osteopathic Medicine, USA |
Lake Erie College of Osteopathic Medicine, USA |
Laval University, Canada |
Leiden University Medical Center, The Netherlands |
Lincoln's Inn Fields Laboratories, UK |
Linnaeus University, Sweden |
Loyola University Medical Center. USA |
Lund University, Sweden |
Lundbeck Research USA, USA |
Max Planck Institute for Biophysical Chemistry, Germany |
McGill University, Canada |
McGill University, Meakins-Christie Laboratories, Canada |
McMaster University, Canada |
Medical College of Georgia, USA |
Medical University of Lodz, Poland |
Medical University of South Carolina, USA |
Medical University of South Carolina, USA |
Medical University of Vienna (MUV), Austria |
Memorial Sloan-Kettering Cancer Center, USA |
Merck In-Licensing, China |
Microbiology Sapienza University of Rome, Italy |
Monash University, Australia |
Moores UCSD Cancer Center, USA |
Moscow State University (MSU), Russia |
N.N.Voroztsov Institute of Organic Chemistry SB RAS, Russia |
N.N.Voroztsov Institute of Organic Chemistry SB RAS, Russia |
Nanyang Technological University, Singapore |
National Institute of Chemistry, Slovenia |
National Research Council (CNR), Italy |
New York State Psychiatric Institute, USA |
New York-Presbyterian Hospital/Columbia University Medical Center, USA |
Northeast Agriculture University, China |
Novartis Institutes for BioMedical Research, USA |
NYU School of Medicine, USA. |
Oncology Roswell Park Cancer Institute Buffalo, USA |
Oregon Health & Science University, USA |
Osaka Prefecture University, Japan |
Paediatric Oncology Research, Medico-surgical Paediatric Department (DMCP), Switzerland |
Pfizer, USA |
Physiology-Pharmacology and environmental Health Laboratory, Morocco |
Pierre and Marie Curie University, France |
Polish Academy of Sciences, Poland |
Pontifical Catholic University of Rio Grande do Sul, Brazil |
Psychiatry UMKC School of Medicine, USA |
Queen's University, UK |
Radboud University, The Netherlands |
Rashtrasant Tukadoji Maharaj Nagpur University, India |
Research Unit PASTEUR, France |
Research Unit for Biomedical Informatics, Spain |
Roche R&D China, China |
Shanxi Medical University, China |
Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Russia |
Shujitsu University School of Pharmacy, Japan |
SloanCKettering Institute for Cancer, USA |
Soochow University, China |
Southern Alberta Cancer Research Institute, Canada |
Stanford University, USA |
Stony Brook University, USA |
Sub Dean International, Faculty of Science, Australia |
Sungkyunkwan University School of Medicine, South Korea |
Sunnybrook Health Sciences Centre, Canada |
Tel Aviv University, Israel |
Terry Fox Laboratory, BC Cancer Research Center, Canada |
The Angeles Clinic and Research Institute, USA |
The George Washington University Medical Faculty Associates., USA |
The University of Texas Health Science Center at Tyler, USA |
The University of Tokyo, Japan |
Tianjin Medical University |
TNO BioSciences, The Netherlands |
Tokushima Bunri University, Japan |
Tongji Medical college, China |
Translational Medicine Research Centre, MSD, Singapore |
Tsinghua University, China |
Tufts Medical Center, USA |
Turku University, Finland |
UCDavis School of Medicine, USA |
Universidad de Buenos Aires, Argentina |
University College London, UK |
University Hospital Basel, Switzerland |
University Hospital of Iceland, Iceland |
University of Basel, Switzerland |
University of Basilicata, Italy |
University of Bayreuth, Germany |
University of Berne, Switzerland |
University of Birmingham, UK |
University of Bologna, Italy |
University of Bologna, Italy |
University of Cagliari, Italy |
University of Cologne, Germany |
University of Colorado Denver Anschutz Medical Campus, USA |
University of Colorado Denver, USA |
University of Copenhagen, Denmark |
University of Debrecen, Hungary |
University of Dundee, UK |
University of Edinburgh, ISB, School of Biological Sciences, UK |
University of Florida, USA |
University of G?ttingen Medical School, Germany |
University of Granada, Spain |
University of Hyderabad, India |
University of Leicester, UK |
University of Liverpool, UK |
University of Louisville in Louisville, USA |
University of Manitoba, Canada |
University of Massachusetts Medical School, USA |
University of Medicine & Dentistry of New Jersey and VA Medical Center, USA |
University of Miami Medical School, USA |
University of Milan, Italy |
University of Minnesota Medical School, USA |
University of Minnesota, USA |
University of Missouri-Columbia School of MedicineUSA |
University of Miyazaki, Japan |
University of Nice Sophia Antipolis, France |
University of Nice Sophia Antipolis, France |
University of Oxford, Uk |
University of Oxford, UK |
University of Pennsylvania, USA |
University of Pittsburgh School of Medicine, USA |
University of Pittsburgh School of Medicine, USA |
University of Rio de Janeiro Medical School, Brazilian Brain Institute, Brazil |
University of Rome "Tor Vergata", Italy |
University of Science & Technology in Korea, Korea |
University of Sherbrooke, Canada |
University of Sherbrooke, Canada |
University of South Alabama, USA |
University of Southern Nevada College of Pharmacy, USA |
University of Strasbourg, France |
University of Tasmania, Australia |
University of Tasmania, Australia |
University of Tennessee College of Veterinary Medicine, USA |
University of Texas Houston Medical School, USA |
University of the Incarnate Word, USA |
University of Udine, Italy |
University of Western Sydney, Australia |
University of Wisconsin School of Medicine and Public Health, USA |
University of Wisconsin-Milwaukee, USA |
University of Wisconsin-Whitewater, USA |
University of Munich, Germany |
Uppsala University, Sweden |
USA Mitchell Cancer Institute, USA |
UT Southwestern Medical Center, USA |
Victoria University, Australia |
Virginia Commonwealth University, USA |
VIT University, India |
Weill Cornell Medical College in Qatar, Qatar |
Weill Cornell Medical College, USA |
Weill Medical College of Cornell University, USA |
Wroclaw Medical University, Poland |
Yale University School of Medicine, USA |
| Menoufyia University, Egypt |
|
Participants List
(Business) |
A*STAR, Singapore |
Abbott Park, USA |
Addex Pharmaceuticals, Switzerland |
?terna Zentaris, Germany |
Agilent Technologies, USA |
Alacrita LLP, UK |
AstraZeneca Pharmaceuticals LP, USA |
AstraZeneca KK, Japan |
Avanti Group of Companies, USA |
Banyan Biomarkers, Inc., USA |
Beth Israel Deaconess Medical Center, USA |
Biocept, Inc., USA |
BiogenIdec Inc. USA |
Boehringer Ingelheim Pharma GmbH & Co. KG, Germany |
Boehringer Ingelheim Pharmaceuticals, Inc., USA |
Boehringer Ingelheim Pharmaceuticals, USA |
Bridge Laboratories, China |
Bristol Myers Squibb, USA |
Bristol-Myers Squibb Co., USA |
Caerus Consulting Pty. Ltd, Australia |
Caprotec Bioanalytics GmbH, Germany |
Cellx Inc., USA |
Charite Virchow Klinikum, Germany. |
Chemizon, Inc., China |
Chrysalis Pharma Consulting, LLC, USA |
Cisbio Bioassays, France |
Close Concerns, Inc., USA |
CodexBiosolutions, USA |
Collegium Internationale Neuro-Psychopharmacologicum (CINP), Sweden |
Crown BioScience, Inc., USA |
Daiichi Sankyo Pharma Development, USA |
Dr. Behçet Uz Children's Hospital, Turkey |
Dr. Siyami Ersek Hospital, Turkey |
Eli Lilly and Company, USA |
Environmental Health Foundation, USA |
European ScreeningPort GmbH, Germany |
F. Hoffmann-La Roche Ltd, Switzerland |
Foley & Lardner LLP, USA |
Freeman Hospital, UK |
Fulford India Ltd(Subsidiary of Schering Plough Corporation USA), India |
Genentech, Inc., USA |
GlaxoSmithKline Pharmaceuticals, UK |
GlaxoSmithKline, USA |
Hamamatsu Photonics K.K., Japan |
Health and Human Services, USA |
Hirslanden Private Hospital Group, Switzerland |
Hoffmann-La Roche Inc., USA |
HoffmannCLa Roche Inc., USA |
Hospital for Special Surgery, USA |
Hospital Geral, Goiania, Brazil |
Hospital Henri Mondor, France |
IHMA Europe Sarl, Switzerland |
Inamed Research GmbH & Co., Germany |
ITHW, Inc., USA |
Johnson and Johnson Pharmaceuticals, Belgium |
Kaiser Oakland Medical Center, USA |
KEM Hospital, India |
Mayo Clinic, USA |
McLean Hospital, USA |
Medication Delivery--Baxter Healthcare, USA |
Merck & Co., USA |
Monogram Biosciences, Inc., USA |
Musgrove Park Hospital, UK |
NeuroProof GmbH, Germany |
New York Harbor HCS, USA |
Novalead Pharma Pvt. Ltd., India |
Novartis Pharma AG, Switzerland |
Novartis, USA |
ObeTherapy, France |
Octagon Research Solutions, USA |
Oramed Pharmaceutical Inc., USA |
Orion Pharma, Finland |
Paracelsus-Hospital, Germany |
Pfizer (China) R&D, China |
Pfizer Global Research and Development, UK |
Philip Morris Research Laboratories GmbH, Germany |
Primus Pharmaceuticals, Inc., USA |
Profil Institute for Clinical Research Inc., USA |
Ramot at Tel Aviv University Ltd., Israel |
Ranbaxy Laboratories Ltd., India |
Real Data Medical Research Inc., China |
Roche Pharma Partnering, USA |
Rosetta Genomics, USA |
S & P, Biotech & Pharma Investment, USA |
S*BIO Pte Ltd., Singapore |
San Carlo Hospital of Potenza and Madonna delle Grazie Hospital of Matera, Italy |
Sanofi-Pasteur, Canada |
Santaris pharma a/s, RNA Medicines for the 21st Century, Danmark |
Schering Plough Corporation, The Netherlands |
Somagenics, Inc., USA |
Sovicell GmbH, Germany |
St. Jude Childrens Research Hospital, USA |
St. Luke's Episcopal Hospital, USA |
Supercomputing Center (BSC), Spain |
Threshold Pharmaceuticals Inc., USA |
Threshold Pharmaceuticals Inc., USA |
TWI Pharma, Taiwan |
Vastrata Ltd, UK |
Westmead Hospital, Australia |
Wyeth Research, USA |
|
 |
|
|
|
|
|
|
| Schedule |
|
Program Schedule
Time: October 23-26, 2010
Place: Beijing International Convention Center (BICC), China
Beijing Continental Grand Hotel (BCGH), China
Date |
Time |
Activities |
Venue |
October 22, 2010
(Friday) |
08:00-20:00 |
Registration |
3rd Floor, BICC |
October 23, 2010
(Saturday Morning) |
08:20-08:40 |
Group Photo |
Outside Square, BICC |
09:00-11:20 |
Opening Ceremony & Keynote Lectures |
Room No. 2, 2nd Floor, BICC |
October 23, 2010
(Saturday Afternoon) |
13:30-17:35 |
Section 1-1: Oncology and Drug Discovery (Part I) |
Room No. 301, 3rd Floor, BICC |
13:30-14:45 |
Section 2-1: Genomics, Proteomics and Metabolomics in Drug Discovery and Target Validation |
Room No. 203B, 3rd Floor, BICC |
13:30-16:45 |
Section 2-2: Advancing Molecular Target Discovery and Drug Screening |
Room No. 305C, 3rd Floor, BICC |
15:30-18:00 |
Section 2-3: Biomarkers for Drug Discovery |
Room No. 203B, 3rd Floor, BICC |
15:30-18:00 |
Section 3-1-1: Novel Target and Biomarker of Cardiovascular Diseases |
Room No. 203A, 3rd Floor, BICC |
13:30-17:10 |
Section 3-2-1: Drug Discovery Targeting Alzheimer' s Disease (Part I) |
Room No. 302, 3rd Floor, BICC |
13:30-15:10 |
Section 3-2-2: Drug Discovery Targeting Parkinson' s Disease |
Room No. 203A, 3rd Floor, BICC |
13:30-16:45 |
Section 3-4-1: Drug Discovery Targeting Asthma and Chronic Obstructive Pulmonary Disease (COPD) |
Room No. 303, 3rd Floor, BICC |
13:30-16:45 |
Section 3-4-2: Anti-Inflammatory Drugs |
Room No. 310, 3rd Floor, BICC |
13:30-14:45 |
Section 3-7-1: Challenges and Opportunities |
Room No. 311A, 3rd Floor, BICC |
15:30-17:10 |
Section 3-7-2: Antibacterial Drug Resistance Drug Discovery |
Room No. 311A, 3rd Floor, BICC |
13:30-16:45 |
Section 3-8: MDR/XDR-TB and Malaria Drug Discovery |
Room No. 308, 3rd Floor, BICC |
13:30-16:45 |
Section 4-1: Receptors and Ion Channel Based Drug Design and Medicinal Chemistry |
Room No. 311B, 3rd Floor, BICC |
13:30-17:35 |
Section 5-1: Innovations and Improvement of Major Biotherapeutics |
Room No. 311C, 3rd Floor, BICC |
13:30-16:45 |
Section 6-1: New Formulation and Drug Delivery System Development |
Room No. 306, 3rd Floor, BICC |
13:30-17:35 |
Section 7-1: Scientific Revisit of Major TCM Combinatorial Formulations |
Room No. 312, 3rd Floor, BICC |
13:30-15:10 |
Section 8-1: Translational Medicine and Globalization Strategies (Part I) |
Room No. 307, 3rd Floor, BICC |
15:30-17:30 |
Section 8-2: Translational Medicine and Globalization Strategies (Part II) |
Room No. 307, 3rd Floor, BICC |
18:30-20:30 |
Welcome Banquet and Art Performance |
Hotel Garden, BCGH |
October 24, 2010
(Sunday Morning) |
08:30-10:55 |
Section 1-2: Endocrinology and Drug Discovery |
Room No. 305A, 3rd Floor, BICC |
08:30-11:20 |
Section 1-3: Personalized Medicine and Drug Discovery |
Room No. 305B, 3rd Floor, BICC |
08:30-11:45 |
Section 2-4: Bioinformatics/Chemoinformatics and Bio-IT/Pharm-IT for Drug Discovery |
Room No. 305C, 3rd Floor, BICC |
08:30-12:10 |
Section 2-8: HPLC/GC, LC/GC-MS, Maldi-TOF and Structure Biology for Drug Discovery (Part I) |
Room No. 301, 3rd Floor, BICC |
08:30-09:45 |
Section 3-2-3: Drug Discovery Targeting Alzheimer's Disease (Part II) |
Room No. 302, 3rd Floor, BICC |
10:30-11:45 |
Section 3-2-4: Drug Discovery Targeting Amyotrophic Lateral Sclerosis |
Room No. 302, 3rd Floor, BICC |
08:30-11:45 |
Section 3-5: Mental Disease Drug Discovery |
Room No. 303, 3rd Floor, BICC |
10:55-12:10 |
Session 3-7-3: Antifungal and Antiviral Drug Discovery |
Room No. 305A, 3rd Floor, BICC |
October 24, 2010
(Sunday Afternoon) |
13:30-17:35 |
Section 1-1: Oncology and Drug Discovery (Part II) |
Room No. 305C, 3rd Floor, BICC |
13:30-15:55 |
Section 1-4: Pharmacology and Drug Discovery |
Room No. 305A, 3rd Floor, BICC |
13:30-17:10 |
Section 1-5: Neurosciences and Drug Discovery (Part I) |
Room No. 305B, 3rd Floor, BICC |
15:55-16:45 |
Section 1-8: Stem Cell and Regenerative Medicine |
Room No. 305A, 3rd Floor, BICC |
13:30-14:45 |
Section 2-5: Biochips, Microarray and Molecular Imaging for Drug Discovery |
Room No. 301, 3rd Floor, BICC |
15:30-17:10 |
Section 2-6: miRNA, siRNA/RNAi and Small RNA Technology in Drug Discovery |
Room No. 301, 3rd Floor, BICC |
13:30-17:30 |
Section 2-13: Novel Drug Delivery from New Materials to Nanotechnology (Part I) |
Room No. 302, 3rd Floor, BICC |
13:30-14:20 |
Section 3-3-1: Emerging Targets for Diabetes Drug Discovery - From Genetics, Biomarkers, Signal Transduction to Biochemical Mechanisms |
Room No. 303, 3rd Floor, BICC |
14:20-17:10 |
Section 3-3-2: Beyond Insulin Therapy - Insulin Improvement, Incretin and Anti-Insulin Resistant Therapeutics Development |
Room No. 303, 3rd Floor, BICC |
October 25, 2010
(Monday Morning) |
08:30-12:10 |
Section 1-1: Oncology and Drug Discovery (Part III) |
Room No. 305B, 3rd Floor, BICC |
08:30-11:45 |
Section 1-7: Formulation in Drug Discovery |
Room No. 305A, 3rd Floor, BICC |
08:30-09:20 |
Section 2-7: Advanced Cell-based to Tissue-based Assays |
Room No. 305C, 3rd Floor, BICC |
10:30-12:10 |
Section 2-8: HPLC/GC, LC/GC-MS, Maldi-TOF and Structure Biology for Drug Discovery (Part II) |
Room No. 305C, 3rd Floor, BICC |
08:30-11:45 |
Section 3-1-2: The Cholesterol and Lipid Management New Drug Discovery |
Room No. 301, 3rd Floor, BICC |
08:30-10:10 |
Section 3-3-3: Progress in Non-insulin Antidiabetics – Targeting Type 2 Diabetes |
Room No. 302, 3rd Floor, BICC |
10:30-12:10 |
Section 3-3-4: Targeting Diabetes Related Metabolic Complications - From Foot, Eye, Inflammation, Cardiovascular, Macrovascular to Nephropathy |
Room No. 302, 3rd Floor, BICC |
08:30-10:10 |
Section 3-6: Autoimmune and Other Severe Immune Diseases |
Room No. 303, 3rd Floor, BICC |
08:30-12:10 |
Section 4-2: Computer Aided Drug Design and SAR Studies |
Room No. 310, 3rd Floor, BICC |
10:30-11:45 |
Section 6-2: Clinical Pharmacology and Efficacy Research Progress |
Room No. 303, 3rd Floor, BICC |
October 25, 2010
(Monday Afternoon) |
13:30-15:10 |
Section 1-5: Neurosciences and Drug Discovery (Part II) |
Room No. 305A, 3rd Floor, BICC |
15:30-17:35 |
Section 1-6: Toxicology, Drug Safety Evaluation and Drug Discovery |
Room No. 305A, 3rd Floor, BICC |
13:30-16:20 |
Section 1-9: Microbiology, Virology and Drug Discovery |
Room No. 305B, 3rd Floor, BICC |
13:30-17:35 |
Section 2-9: Novel DMPK and ADMET Technologies |
Room No. 305C, 3rd Floor, BICC |
13:30-14:20 |
Section 2-10: Validated Animal Models in Drug Discovery |
Room No. 301, 3rd Floor, BICC |
15:30-17:35 |
Section 2-11: New Kinase Inhibitors |
Room No. 301, 3rd Floor, BICC |
13:30-17:10 |
Section 2-13: Novel Drug Delivery from New Materials to Nanotechnology (Part II) |
Room No. 302, 3rd Floor, BICC |
13:30-14:45 |
Section 3-3-5: Alternative Medicines for Anti-Diabetes Treatment - From Single Natural Products to Chinese Traditional Medicines |
Room No. 303, 3rd Floor, BICC |
15:30-17:35 |
Section 3-3-6: Drug Discovery Targeting Obesity - From Drug Targets to Novel Molecules |
Room No. 303, 3rd Floor, BICC |
13:30-15:10 |
Section 3-9-1: Anti-AIDS, Anti-Avian Flu, and Anti-H1N1 Drug Discovery |
Room No. 310, 3rd Floor, BICC |
15:30-17:35 |
Section 3-9-2: Anti-HCV Drug Discovery |
Room No. 310, 3rd Floor, BICC |
13:30-16:45 |
Section 4-3: Structure-Based Drug Design and Medicinal Chemistry |
Room No. 311A, 3rd Floor, BICC |
October 26, 2010
(Tuesday Morning) |
08:30-10:10 |
Section 1-10: Clinical Medicine and Drug Discovery |
Room No. 305A, 3rd Floor, BICC |
08:30-11:50 |
Section 2-12: GPCR-based Drug Discovery |
Room No. 305B, 3rd Floor, BICC |
10:30-11:45 |
Section 2-14: Supporting Systems for Major Innovative Drugs |
Room No. 305A, 3rd Floor, BICC |
08:30-11:20 |
Section 4-4: Improving ADME/DMPK Profile, Reducing DDI/Toxicity, and Overcoming Formulation Difficulties |
Room No. 305C, 3rd Floor, BICC |
08:30-10:10 |
Section 6-3: Global Regulatory and IP Issues in Biosimilar Development |
Room No. 301, 3rd Floor, BICC |
10:30-11:45 |
Section 6-4: Opportunities and Challenges for Biosimilars |
Room No. 301, 3rd Floor, BICC |
08:30-11:10 |
Section 7-2: Major Bioactive Herb Fraction Discovery from Acting Mechanism Studies to Safety Evaluation |
Room No. 302, 3rd Floor, BICC |
11:20-12:10 |
Section 7-3: Reliable QC/QA Method and Standard Development |
Room No. 302, 3rd Floor, BICC |
08:30-11:20 |
Section 9-1: Integrated Services & Partnership for Drug Discovery |
Room No. 308, 3rd Floor, BICC |
08:30-12:10 |
Section 9-2: CRO, CMO and FTE in Chemistry & Biology |
Room No. 303, 3rd Floor, BICC |
08:30-11:20 |
Section 9-3: Outsourcing in Clinical Studies |
Room No. 310, 3rd Floor, BICC |
08:30-12:10 |
Symposium 1: Emerging Targets, Pathways, Biomarkers and Validation |
Room No. 311A, 3rd Floor, BICC |
08:30-11:20 |
Symposium 2: Advances in Other Existing Validated Cancer Drug Targets |
Room No. 311B, 3rd Floor, BICC |
08:30-11:45 |
Symposium 3: Anticancer Biotherapeutics Discovery and Development |
Room No. 311C, 3rd Floor, BICC |
08:30-10:55 |
Symposium 4: Nanomedicine and Targeted Cancer Drug Delivery System |
Room No. 306, 3rd Floor, BICC |
08:30-12:10 |
Symposium 5: Advances of Drug Discovery against Major Cancers |
Room No. 312, 3rd Floor, BICC |
11:20-12:20 |
Patch Clamp Workshop |
Room No. 305C, 3rd Floor, BICC |
|
|